Towa Pharmaceutical Co., Ltd.
4553.T · JPX
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Revenue | ¥259,594,000 | ¥227,934,000 | ¥208,859,000 | ¥165,615,000 |
| % Growth | 13.9% | 9.1% | 26.1% | – |
| Cost of Goods Sold | ¥164,865,000 | ¥146,551,000 | ¥136,145,000 | ¥95,429,000 |
| Gross Profit | ¥94,729,000 | ¥81,383,000 | ¥72,714,000 | ¥70,186,000 |
| % Margin | 36.5% | 35.7% | 34.8% | 42.4% |
| R&D Expenses | ¥16,212,000 | ¥13,242,000 | ¥15,265,000 | ¥11,488,000 |
| G&A Expenses | ¥0 | ¥0 | ¥0 | ¥0 |
| SG&A Expenses | ¥71,486,000 | ¥50,494,000 | ¥51,934,000 | ¥40,160,000 |
| Sales & Mktg Exp. | ¥0 | ¥0 | ¥0 | ¥0 |
| Other Operating Expenses | -¥16,212,000 | ¥0 | ¥0 | -¥668,000 |
| Operating Expenses | ¥71,486,000 | ¥63,736,000 | ¥67,199,000 | ¥50,980,000 |
| Operating Income | ¥23,243,000 | ¥17,647,000 | ¥5,514,000 | ¥19,205,000 |
| % Margin | 9% | 7.7% | 2.6% | 11.6% |
| Other Income/Exp. Net | ¥3,087,000 | ¥6,812,000 | -¥909,000 | ¥3,041,000 |
| Pre-Tax Income | ¥26,330,000 | ¥24,459,000 | ¥4,605,000 | ¥22,246,000 |
| Tax Expense | ¥7,343,000 | ¥8,286,000 | ¥2,404,000 | ¥6,331,000 |
| Net Income | ¥18,986,000 | ¥16,173,000 | ¥2,201,000 | ¥15,914,000 |
| % Margin | 7.3% | 7.1% | 1.1% | 9.6% |
| EPS | 385.7 | 328.58 | 44.72 | 323.35 |
| % Growth | 17.4% | 634.7% | -86.2% | – |
| EPS Diluted | 385.7 | 328.58 | 44.72 | 316.19 |
| Weighted Avg Shares Out | 49,225 | 49,221 | 49,222 | 49,216 |
| Weighted Avg Shares Out Dil | 49,225 | 49,221 | 50,342 | 50,325 |
| Supplemental Information | – | – | – | – |
| Interest Income | ¥221,000 | ¥97,000 | ¥17,000 | ¥8,000 |
| Interest Expense | ¥1,627,000 | ¥947,000 | ¥635,000 | ¥230,000 |
| Depreciation & Amortization | ¥20,099,000 | ¥17,888,000 | ¥19,409,000 | ¥10,954,000 |
| EBITDA | ¥48,055,000 | ¥35,536,000 | ¥25,143,000 | ¥29,492,000 |
| % Margin | 18.5% | 15.6% | 12% | 17.8% |